X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4200) 4200
Publication (531) 531
Book Review (61) 61
Book Chapter (20) 20
Conference Proceeding (9) 9
Magazine Article (4) 4
Book / eBook (2) 2
Trade Publication Article (2) 2
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rituximab (3539) 3539
humans (3245) 3245
index medicus (2417) 2417
female (1320) 1320
male (1268) 1268
oncology (1208) 1208
middle aged (1073) 1073
pharmacology & pharmacy (1059) 1059
antibodies, monoclonal, murine-derived (946) 946
adult (869) 869
aged (840) 840
antibodies, monoclonal - therapeutic use (769) 769
therapy (743) 743
treatment outcome (731) 731
animals (717) 717
antibodies, monoclonal - pharmacology (669) 669
non-hodgkins-lymphoma (643) 643
hematology (597) 597
immunology (544) 544
antineoplastic agents - pharmacology (523) 523
antineoplastic combined chemotherapy protocols - therapeutic use (521) 521
chemotherapy (515) 515
antineoplastic agents - therapeutic use (511) 511
lymphoma (490) 490
cancer (469) 469
lymphomas (435) 435
chronic lymphocytic-leukemia (418) 418
monoclonal antibodies (399) 399
mice (391) 391
b-cell lymphoma (372) 372
care and treatment (369) 369
cell line, tumor (364) 364
immunotherapy (363) 363
antigens, cd20 - immunology (358) 358
aged, 80 and over (352) 352
anti-cd20 monoclonal-antibody (352) 352
cyclophosphamide (341) 341
medicine, research & experimental (341) 341
antibodies, monoclonal, murine-derived - therapeutic use (340) 340
antibodies, monoclonal - administration & dosage (329) 329
transplantation (313) 313
antibodies, monoclonal, murine-derived - pharmacology (310) 310
apoptosis (302) 302
b-lymphocytes - drug effects (299) 299
drug therapy (299) 299
b-lymphocytes - immunology (294) 294
leukemia, lymphocytic, chronic, b-cell - drug therapy (284) 284
hemic and lymphatic diseases (267) 267
analysis (262) 262
antibodies, monoclonal, murine-derived - administration & dosage (260) 260
rheumatoid arthritis (260) 260
monoclonal-antibody (259) 259
research (256) 256
rituximab - therapeutic use (255) 255
patients (253) 253
prognosis (252) 252
efficacy (249) 249
cd20 (247) 247
lymphoma, non-hodgkin - drug therapy (247) 247
antibodies (244) 244
expression (243) 243
lymphoma, large b-cell, diffuse - drug therapy (240) 240
medicine & public health (239) 239
trial (239) 239
immunologic factors - therapeutic use (238) 238
follicular lymphoma (237) 237
lymphoma, b-cell - drug therapy (236) 236
survival (235) 235
immunosuppressive agents - therapeutic use (234) 234
disease-free survival (232) 232
cyclophosphamide - administration & dosage (222) 222
health aspects (222) 222
antibodies, monoclonal - adverse effects (221) 221
retrospective studies (221) 221
apoptosis - drug effects (220) 220
rituximab - pharmacology (215) 215
disease (212) 212
immune system diseases (212) 212
double-blind (211) 211
rheumatoid-arthritis (211) 211
young adult (199) 199
leukemia (198) 198
rheumatology (197) 197
time factors (195) 195
adolescent (192) 192
phase-ii (192) 192
in-vivo (190) 190
recurrence (189) 189
antineoplastic agents - administration & dosage (188) 188
antineoplastic combined chemotherapy protocols - administration & dosage (188) 188
lymphocytes b (188) 188
clinical trials as topic (187) 187
pharmacology (187) 187
safety (185) 185
b cells (184) 184
arthritis, rheumatoid - drug therapy (183) 183
abridged index medicus (179) 179
antibodies, monoclonal - immunology (179) 179
clinical trials (178) 178
internal medicine (177) 177
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4109) 4109
Spanish (27) 27
French (26) 26
Japanese (19) 19
Chinese (14) 14
Russian (10) 10
German (8) 8
Italian (4) 4
Czech (2) 2
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 36, pp. 58142 - 58147
The bromodomain inhibitor OTX015 (MK-8628) has shown anti-lymphoma activity as a single agent in both the preclinical and clinical settings, as well as in... 
Rituximab | BET inhibitor | Everolimus | Vorinostat | Ibrutinib | vorinostat | NEOPLASMS | TRANSCRIPTION | CELL BIOLOGY | ibrutinib | IDENTITY | DOSE-ESCALATION | ACUTE-LEUKEMIA | everolimus | B-CELL LYMPHOMA | SUPER-ENHANCERS | MODELS | PHASE-1 | rituximab | Pyrazoles - therapeutic use | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Rituximab - therapeutic use | Acetanilides - therapeutic use | Everolimus - therapeutic use | Antineoplastic Agents - pharmacology | Hydroxamic Acids - pharmacology | Molecular Targeted Therapy - methods | Pyrazoles - pharmacology | Acetanilides - pharmacology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Everolimus - pharmacology | Lymphoma, Large B-Cell, Diffuse - pathology | Pyrimidines - pharmacology | Mice, SCID | Drug Synergism | Rituximab - pharmacology | Xenograft Model Antitumor Assays | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Heterocyclic Compounds, 3-Ring - therapeutic use | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Mice, Inbred NOD | Histone Deacetylase Inhibitors - therapeutic use | Mice | Protein Kinase Inhibitors - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
BioMed research international, ISSN 2314-6133, 2018, Volume 2018, pp. 1023490 - 9
The antibody-dependent cell-mediated cytotoxicity (ADCC) of the anti-CD20 monoclonal antibodies (mAbs) rituximab and obinutuzumab against the cell line Raji... 
PRECLINICAL ACTIVITY | MEDICINE, RESEARCH & EXPERIMENTAL | IN-VITRO | EFFICACY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | RITUXIMAB | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | THERAPEUTIC ANTIBODIES | KINASE INHIBITORS | MONOCLONAL-ANTIBODIES | GA101 | Leukocytes, Mononuclear - metabolism | Leukocytes, Mononuclear - drug effects | Purines - pharmacology | Antibodies, Monoclonal - pharmacology | Humans | Antigens, CD20 - metabolism | Pyrimidines - pharmacology | Receptors, Antigen, B-Cell - metabolism | Rituximab - pharmacology | B-Lymphocytes - drug effects | Cytotoxins - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Cell Line, Tumor | Benzamides - pharmacology | Killer Cells, Natural - drug effects | Protein Kinase Inhibitors - pharmacology | Antibody-Dependent Cell Cytotoxicity - drug effects | Pyrazines - pharmacology | Quinazolinones - pharmacology | Pyrazoles - pharmacology | Toxicity | Leukemia | Impairment | Effector cells | Cytotoxicity | Leukocytes (mononuclear) | B-cell receptor | Kinases | Peripheral blood mononuclear cells | Natural killer cells | Calcein | Genetic modification | Recombinant | Antibody-dependent cell-mediated cytotoxicity | Immunoglobulins | Chronic lymphatic leukemia | Comorbidity | Interference | Rituximab | Lactate dehydrogenase | T cell receptors | Bruton's tyrosine kinase | L-Lactate dehydrogenase | CD16 antigen | Inhibitors | Lymphocytes B | Cell lines | Monoclonal antibodies | CD20 antigen | Lymphomas | Lactic acid
Journal Article
Haematologica, ISSN 0390-6078, 01/2002, Volume 87, Issue 1, pp. 33 - 43
University Hospital, Department of Internal Medicine III, Hematology and Oncology, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany. BACKGROUND AND... 
Anti-CD20 | Complement | Bendamustine | Cytokines | Apoptosis | CD20 | anti-CD20 | INDUCED APOPTOSIS | HUMAN MONOCLONAL-ANTIBODY | apoptosis | COMBINATION | B-CELL LYMPHOMA | IN-VITRO | NON-HODGKINS-LYMPHOMA | cytokines | CYTOMETRY | complement | HEMATOLOGY | EXPRESSION | bendamustine | JC-1 | Caspases - physiology | Caspase 9 | Caspase 8 | Complement System Proteins - pharmacology | Complement Activation | Apoptosis - drug effects | Humans | Neoplasm Proteins - physiology | Antigens, Neoplasm - biosynthesis | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Burkitt Lymphoma - pathology | Amino Acid Chloromethyl Ketones - pharmacology | Lymphoma, B-Cell - immunology | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Interleukins - pharmacology | Caspase 7 | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Antibodies, Monoclonal - immunology | Lymphoma, B-Cell - drug therapy | Antigens, CD20 - immunology | Antigens, Neoplasm - genetics | Rabbits | Antibodies, Monoclonal, Murine-Derived | Antigens, Neoplasm - immunology | Lymphoma, Follicular - pathology | Nitrogen Mustard Compounds - pharmacology | Antibodies, Monoclonal - pharmacology | Tumor Cells, Cultured - drug effects | Gene Expression Regulation, Leukemic - drug effects | Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology | Rituximab | Caspase Inhibitors | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Cladribine - pharmacology | Antigens, CD20 - genetics | Drug Synergism | Tumor Necrosis Factor-alpha - pharmacology | Animals | Bendamustine Hydrochloride | Antigens, CD20 - biosynthesis | Cysteine Proteinase Inhibitors - pharmacology | Lymphoma, B-Cell - pathology | Mitoxantrone - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Oligopeptides - pharmacology | Doxorubicin - pharmacology
Journal Article
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 2014, pp. e317 - e325
Journal Article
Journal Article
Annals of Neurology, ISSN 0364-5134, 04/2010, Volume 67, Issue 4, pp. 452 - 461
Journal Article
Nature Communications, ISSN 2041-1723, 04/2016, Volume 7, Issue 1, p. 11138
Journal Article
Experimental Cell Research, ISSN 0014-4827, 05/2011, Volume 317, Issue 8, pp. 1179 - 1191
Prenylation is a post-translational hydrophobic modification of proteins, important for their membrane localization and biological function. The use of... 
Prenylation | Non-Hodgkin's lymphoma | Rab GGT | Isoprenoids | MULTIPLE-MYELOMA | RITUXIMAB-CHOP | REDUCTASE INHIBITOR | INDUCED APOPTOSIS | STATIN USE | DRUG-RESISTANCE | PROTEIN GERANYLGERANYLATION | CELL BIOLOGY | ONCOLOGY | KAPPA-B PATHWAY | SMALL GTPASES | MOLECULAR-MECHANISMS | Doxorubicin - therapeutic use | Vincristine - pharmacology | Humans | Alkyl and Aryl Transferases - metabolism | Alkyl and Aryl Transferases - antagonists & inhibitors | Drug Resistance, Neoplasm | Methionine - pharmacology | Cell Line, Tumor - drug effects | Simvastatin - pharmacology | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Farnesyltranstransferase - metabolism | Methionine - analogs & derivatives | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Farnesyltranstransferase - antagonists & inhibitors | Cell Death - drug effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Cell Survival | Enzyme Inhibitors - pharmacology | Rituximab | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cyclophosphamide - pharmacology | Vincristine - therapeutic use | Cell Cycle - physiology | Prednisone - pharmacology | Antibodies, Monoclonal, Murine-Derived - pharmacology | Doxorubicin - pharmacology | Prednisone - therapeutic use | Biochemistry | Non-Hodgkin's lymphomas | Cell death | Analysis | Sensitivity | Models | Cells | LYMPHOMAS | APOPTOSIS | BIOLOGICAL FUNCTIONS | INHIBITION | THERAPY | SENSITIVITY | TUMOR CELLS | PROTEINS | 60 APPLIED LIFE SCIENCES | Clinical Medicine | Medical and Health Sciences | Hematologi | Hematology | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2015, Volume 169, Issue 4, pp. 506 - 519
Journal Article
American Journal of Physiology - Regulatory Integrative and Comparative Physiology, ISSN 0363-6119, 08/2012, Volume 303, Issue 4, pp. R353 - R358
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2013, Volume 162, Issue 5, pp. 657 - 669
Summary Targeting the proteasome system with bortezomib (BTZ) results in anti‐tumour activity and potentiates the effects of chemotherapy/biological agents in... 
bortezomib | ubiquitin‐proteasome system | B‐cell lymphoma | carfilzomib | Carfilzomib | Bortezomib | Ubiquitin-proteasome system | B-cell lymphoma | CD20 | REFRACTORY MULTIPLE-MYELOMA | MECHANISMS | COMBINATION | CANCER | SINGLE-AGENT | ubiquitin-proteasome system | THERAPY | MALIGNANCIES | HEMATOLOGY | Caspase Inhibitors - pharmacology | Apoptosis - drug effects | Humans | Pyrazines - administration & dosage | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Caspases - metabolism | DNA Fragmentation | Antineoplastic Agents - pharmacology | Boronic Acids - administration & dosage | Cytotoxicity, Immunologic - drug effects | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - metabolism | Drug Screening Assays, Antitumor - methods | Proteasome Inhibitors - pharmacology | Proteasome Inhibitors - administration & dosage | Tumor Cells, Cultured - drug effects | Rituximab | Apoptosis Regulatory Proteins - metabolism | Drug Synergism | Up-Regulation - drug effects | Cell Cycle Checkpoints - drug effects | Lymphoma, B-Cell - pathology | Oligopeptides - administration & dosage | Antibodies, Monoclonal, Murine-Derived - pharmacology | Oligopeptides - pharmacology | Pyrazines - pharmacology | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Ubiquitin | Evaluation | Chemotherapy | Cell cycle | Lymphomas | Antineoplastic agents | Cancer | Apoptosis
Journal Article